Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Company Growth (employees)
Type
Public
HQ
Bagsvaerd, DK
Founded
1923
Size (employees)
41,656 (est)
Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, DK

Key People/Management at Novo Nordisk

Lars Rebien Sørensen

Lars Rebien Sørensen

President & Chief Executive Officer
Jesper Brandgaard

Jesper Brandgaard

EVP and Chief Financial Officer
Maziar Mike Doustdar

Maziar Mike Doustdar

EVP of International Operations
Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

EVP Corporate Developemnt

Novo Nordisk Office Locations

Novo Nordisk has offices in Bagsvaerd, Plainsboro, Mississauga, Mainz and in 138 other locations
Bagsvaerd, DK (HQ)
Novo Nordisk A/S Novo Allé
Tokyo, JP
Meiji Yasuda Seimei Bldg. 2-1-1, Marunouchi, Chiyoda-ku
Beijing, CN
18F, East Tower, World Financial Center, No. 1 East 3rd Ring Middle Road, Chaoyang District
Bangalore, IN
Plot No.32, 47-50, EPIP Area, Whitefield
AV Alphen aan den Rijn, NL
Flemingweg 18
Mainz, DE
Brucknerstrasse 1
Show all (141)

Novo Nordisk Financials and Metrics

Novo Nordisk Financials

USD

Market capitalization (31-Oct-2017)

123.5 b

Closing share price (31-Oct-2017)

49.9
Novo Nordisk's current market capitalization is $123.5 b.
Show all financial metrics

Novo Nordisk Operating Metrics

FY, 2015FY, 2016

Phase III Trials

63

Projects in R&D Pipeline

1917

Patients Reached

26.8 m
Show all operating metrics

Novo Nordisk Market Value History

Novo Nordisk Median Salaries

Source: 33 public H-1B filings from Novo Nordisk
Show all human capital metrics

Novo Nordisk's Web-traffic and Trends

Novo Nordisk Online and Social Media Presence

Novo Nordisk News and Updates

Novo Nordisk preps big obesity push, undeterred by its rivals' failures

Novo Nordisk is about to take on a task that’s so far foiled its peers. The Danish drugmaker is aiming to expand the global obesity market, both by launching its GLP-1 drug Saxenda in additional countries and by lobbying to get obesity recognized as a chronic disease.

Novo Nordisk cutting 185 jobs, adding another 70 in commercial revamp

Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk is embarking on its latest wave of job cuts.

Novo Nordisk looks to Saxenda, semaglutide to squeeze out sales growth as U.S. vise tightens

Novo Nordisk is navigating a tough stretch, thanks to stepped-up competition and new state laws that threaten to worsen pricing pressure in the U.S. But the drugmaker believes it can still come out ahead, provided it can capitalize on some impending drug launches.

Novo Nordisk - Company Profile, SWOT Analysis, Size, Share, Growth, Trends and Opportunities 2017

WiseGuyReports.com adds “Novo Nordisk Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database. Posted via Industry Today. Follow us on Twitter @IndustryToday

With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch

Novo Nordisk is one step closer to approval for semaglutide, the weekly diabetes drug it sees as a best-in-class follow-up to its blockbuster daily injection, Victoza. Next up? FDA label discussions, payer talks and prep for a market tussle with Eli Lilly's Trulicity.

FDA digs into semaglutide CV benefits, eye safety ahead of Novo Nordisk drug's panel review

It's not often that a drug company alerts the media to FDA review documents filed ahead of an agency advisory panel hearing. But Novo Nordisk did just that Monday as its key GLP-1 drug semaglutide, a follow-up to blockbuster Victoza, preps for its close-up before agency experts.
Show more

Novo Nordisk Company Life and Culture

You may also be interested in